000140098 001__ 140098
000140098 005__ 20240321220737.0
000140098 0247_ $$2doi$$a10.1212/WNL.0000000000005690
000140098 0247_ $$2pmid$$apmid:29743208
000140098 0247_ $$2pmc$$apmc:PMC5996832
000140098 0247_ $$2ISSN$$a0028-3878
000140098 0247_ $$2ISSN$$a1526-632X
000140098 0247_ $$2altmetric$$aaltmetric:40937168
000140098 037__ $$aDZNE-2020-06420
000140098 041__ $$aEnglish
000140098 082__ $$a610
000140098 1001_ $$0P:(DE-2719)2812578$$aAziz, Ahmad$$b0$$eFirst author$$udzne
000140098 245__ $$aOverlap between age-at-onset and disease-progression determinants in Huntington disease.
000140098 260__ $$a[S.l.]$$bOvid$$c2018
000140098 264_1 $$2Crossref$$3online$$bOvid Technologies (Wolters Kluwer Health)$$c2018-05-09
000140098 264_1 $$2Crossref$$3print$$bOvid Technologies (Wolters Kluwer Health)$$c2018-06-12
000140098 3367_ $$2DRIVER$$aarticle
000140098 3367_ $$2DataCite$$aOutput Types/Journal article
000140098 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1592235819_17956
000140098 3367_ $$2BibTeX$$aARTICLE
000140098 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000140098 3367_ $$00$$2EndNote$$aJournal Article
000140098 520__ $$aA fundamental but still unresolved issue regarding Huntington disease (HD) pathogenesis is whether the factors that determine age at onset are the same as those that govern disease progression. Because elucidation of this issue is crucial for the development as well as optimal timing of administration of novel disease-modifying therapies, we aimed to assess the extent of overlap between age-at-onset and disease-progression determinants in HD.Using observational data from Enroll-HD, the largest cohort of patients with HD worldwide, in this study we present, validate, and apply an intuitive method based on linear mixed-effect models to quantify the variability in the rate of disease progression in HD.A total of 3,411 patients with HD met inclusion criteria. We found that (1) about two-thirds of the rate of functional, motor, and cognitive progression in HD is determined by the same factors that also determine age at onset, with CAG repeat-dependent mechanisms having by far the largest effect; (2) although expanded HTT CAG repeat size had a large influence on average body weight, the rate of weight loss was largely independent of factors that determine age at onset in HD; and (3) about one-third of the factors that determine the rate of functional, motor, and cognitive progression are different from those that govern age at onset and need further elucidation.Our findings imply that targeting of CAG repeat-dependent mechanisms, for example through gene-silencing approaches, is likely to affect the rate of functional, motor, and cognitive impairment, but not weight loss, in manifest HD mutation carriers.
000140098 536__ $$0G:(DE-HGF)POF3-345$$a345 - Population Studies and Genetics (POF3-345)$$cPOF3-345$$fPOF III$$x0
000140098 588__ $$aDataset connected to CrossRef, PubMed,
000140098 650_2 $$2MeSH$$aAge of Onset
000140098 650_2 $$2MeSH$$aDisease Progression
000140098 650_2 $$2MeSH$$aHumans
000140098 650_2 $$2MeSH$$aHuntington Disease: epidemiology
000140098 650_2 $$2MeSH$$aHuntington Disease: genetics
000140098 650_2 $$2MeSH$$aHuntington Disease: pathology
000140098 7001_ $$0P:(DE-HGF)0$$avan der Burg, Jorien M M$$b1
000140098 7001_ $$0P:(DE-HGF)0$$aTabrizi, Sarah J$$b2
000140098 7001_ $$0P:(DE-HGF)0$$aLandwehrmeyer, G Bernhard$$b3
000140098 77318 $$2Crossref$$3journal-article$$a10.1212/wnl.0000000000005690$$b : Ovid Technologies (Wolters Kluwer Health), 2018-05-09$$n24$$pe2099-e2106$$tNeurology$$v90$$x0028-3878$$y2018
000140098 773__ $$0PERI:(DE-600)1491874-2$$a10.1212/WNL.0000000000005690$$gVol. 90, no. 24, p. e2099 - e2106$$n24$$pe2099-e2106$$q90:24<e2099 - e2106$$tNeurology$$v90$$x0028-3878$$y2018
000140098 8567_ $$2Pubmed Central$$uhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996832
000140098 909CO $$ooai:pub.dzne.de:140098$$pVDB
000140098 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812578$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000140098 9131_ $$0G:(DE-HGF)POF3-345$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$aDE-HGF$$bForschungsbereich Gesundheit$$lErkrankungen des Nervensystems$$vPopulation Studies and Genetics$$x0
000140098 9141_ $$y2018
000140098 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz$$d2022-11-12$$wger
000140098 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-12
000140098 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-12
000140098 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-12
000140098 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-12
000140098 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-12
000140098 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-12
000140098 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROLOGY : 2021$$d2022-11-12
000140098 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-12
000140098 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bNEUROLOGY : 2021$$d2022-11-12
000140098 9201_ $$0I:(DE-2719)1012001$$kAG Breteler 1$$lPopulation Health Sciences$$x0
000140098 980__ $$ajournal
000140098 980__ $$aVDB
000140098 980__ $$aI:(DE-2719)1012001
000140098 980__ $$aUNRESTRICTED